Why the study?
Do statins prevent deterioration of cardiorenal syndrome?
Do statins prevent deterioration of cardiorenal syndrome?
Statins may offer a therapeutic strategy for managing cardiorenal syndrome through their cholesterol-lowering and pleiotropic anti-inflammatory and antioxidant effects.
Answers are grounded in this paper and cite their sources.
May support statin role in cardiorenal syndrome; hypothesis-generating and should not change practice pending RCTs.
Cardiovascular disease and renal disease have a close relationship that forms a vicious cycle as a cardiorenal syndrome (CRS). Oxidative stress, endothelial dysfunction, and vascular inflammation could be therapeutic targets when the renin-angiotensin-aldosterone system is activated by accumulation of conventional cardiovascular risk factors; however, a strategy for management of CRS has not been established yet. Statins, HMG-CoA reductase inhibitors, have not only cholesterol-lowering effects but also pleiotropic effects on cardiovascular systems, including anti-inflammatory and antioxidant effects and improvement of nitric oxide bioavailability. Since recent studies have indicated that statins have beneficial effects on chronic kidney disease and heart failure as well as coronary artery disease in cholesterol-lowering-dependent/independent manners, treatment with statins might be a successful strategy for preventing deterioration of CRS.
No takes yet. Share an insight, caveat, or question.
Yagi et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: